MedPath

PHARMALINK

🇵🇭Philippines
Ownership
-
Employees
-
Market Cap
-
Website

External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group

Active, not recruiting
Conditions
Non-muscle-invasive Bladder Cancer
First Posted Date
2023-05-18
Last Posted Date
2024-04-03
Lead Sponsor
Pharmalink
Target Recruit Count
600
Registration Number
NCT05864599
Locations
🇪🇸

Hospital Vithas 9 d'Octubre, Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath